Abbott Laboratories Q3 2025 Sales Up by 6.9%

By Ahmed Jameison • Wednesday, October 15 15:36 • Permanent Link

Abbott, a global healthcare leader, has reported its financial results for the third quarter of 2025, revealing a 6.9% increase in sales on a reported basis, with organic sales growing by 5.5%. The company's GAAP diluted earnings per share (EPS) for the quarter were $0.94, while the adjusted diluted EPS stood at $1.30.

In terms of year-to-date sales, Abbott saw a 6.1% increase on a reported basis, with organic sales growing by 6.4%. Excluding COVID-19 testing-related sales, the organic sales growth was 7.7%.

Breaking down the performance across its business segments, Abbott's nutrition sales increased by 4.2% on a reported basis and 4.0% on an organic basis in the third quarter. The diagnostic segment, however, experienced a decrease in sales, down by 6.6% on a reported basis and 7.8% organically. Established pharmaceuticals sales grew by 7.5% on a reported basis and 7.1% organically, with key emerging markets driving this growth. Meanwhile, the medical devices segment saw a substantial increase, with sales growing by 14.8% on a reported basis and 12.5% organically in the third quarter.

Looking ahead, Abbott reaffirmed its full-year 2025 organic sales growth guidance and adjusted diluted EPS guidance, narrowing the range to $5.12 to $5.18, reflecting double-digit growth at the midpoint.

Abbott's consistent performance was attributed to its differentiated product pipeline, with the company's chairman and CEO, Robert B. Ford, emphasizing the ability to deliver long-term value to shareholders.

The company also declared its 407th consecutive quarterly dividend, reflecting its commitment to returning value to shareholders, and highlighted its presence as a member of the S&P 500 Dividend Aristocrats index.

Abbott's performance in the third quarter demonstrates its resilience and strong market position across its various business segments, setting the stage for continued growth and value creation in the future. Today the company's shares have moved 1.44% to a price of $133.27. Check out the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.